Menu
Search
|

Menu

Close
X

AcelRx Pharmaceuticals Inc ACRX.OQ (NASDAQ Stock Exchange Global Market)

1.80 USD
-0.05 (-2.70%)
As of 2:29 AM IST
chart
Previous Close 1.85
Open 1.90
Volume 68,795
3m Avg Volume 89,850
Today’s High 1.90
Today’s Low 1.75
52 Week High 5.75
52 Week Low 1.58
Shares Outstanding (mil) 45.38
Market Capitalization (mil) 231.44
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.50 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
7
FY16
17
FY15
19
EPS (USD)
FY17
-0.911
FY16
-0.952
FY15
-0.553
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
14.87
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
--
16.52
LT Debt to Equity (MRQ)
vs sector
--
12.22
Return on Investment (TTM)
vs sector
-63.23
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

Adrian Adams
Independent Chairman of the Board, Since 2013
Salary: --
Bonus: --
Richard King
President, Since 2015
Salary: $490,000.00
Bonus: $91,875.00
Vincent Angotti
Chief Executive Officer, Since 2017
Salary: --
Bonus: --
Raffi Asadorian
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Pamela Palmer
Chief Medical Officer, Director, Since 2005
Salary: $421,000.00
Bonus: $104,987.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

351 Galveston Dr
REDWOOD CITY   CA   94063-4736

Phone: +1650.2163500

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.

SPONSORED STORIES